Quantum Biopharma (QNTM) EBIAT (2019 - 2025)
Quantum Biopharma's EBIAT history spans 7 years, with the latest figure at -$2.3 million for Q4 2025.
- On a quarterly basis, EBIAT fell 10.01% to -$2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$20.8 million, a 752.46% decrease, with the full-year FY2025 number at -$27.0 million, down 80.73% from a year prior.
- EBIAT hit -$2.3 million in Q4 2025 for Quantum Biopharma, up from -$4.8 million in the prior quarter.
- Over the last five years, EBIAT for QNTM hit a ceiling of $49.9 million in Q3 2021 and a floor of -$61.7 million in Q4 2021.
- Historically, EBIAT has averaged -$4.9 million across 5 years, with a median of -$2.1 million in 2024.
- The widest YoY moves for EBIAT: up 468.97% in 2021, down 350.51% in 2021.
- Tracing QNTM's EBIAT over 5 years: stood at -$61.7 million in 2021, then increased by 23.42% to -$47.3 million in 2022, then grew by 26.34% to -$34.8 million in 2023, then surged by 93.99% to -$2.1 million in 2024, then decreased by 10.01% to -$2.3 million in 2025.
- Business Quant data shows EBIAT for QNTM at -$2.3 million in Q4 2025, -$4.8 million in Q3 2025, and -$5.0 million in Q2 2025.